Clopidogrel or prasugrel vs. aspirin monotherapy for long-term secondary prevention after percutaneous coronary intervention for acute coronary syndrome
Optimal long-term antiplatelet monotherapy in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) remains a subject of ongoing debate. In particular, it remains unclear whether different P2Y12 inhibitors provide comparable clinical benefits when used as long-term mon...